300147 Xiangxue Pharmaceutical
- 6.80
- +0.07+1.04%
Xiangxue Pharmaceutical News
Xiangxue Pharmaceutical (300147) Quarterly report comments: 2017 Q1 inventory clearance gradually completed future performance reversal period
Xiangxue Pharmaceutical (300147) Annual report comments: the inventory impact of proprietary Chinese medicines is expected to gradually recover.
Xiangxue Pharmaceutical (300147): endogenous epitaxy to promote precision medical and prepared slices business
Xiangxue Pharmaceutical (300147) Quarterly report comments: the impact of inventory removal is obvious or will benefit from the formula granule policy.
[southwest Securities] Xiangxue Pharmaceutical: the impact of inventory removal is obvious, or it will benefit from the formula granule policy.
Xiangxue Pharmaceutical (300147) Quarterly report comments: traditional business pressure Yinpian and other business continuous layout
[GF Securities Co., LTD.] Xiangxue Pharmaceutical: dragged down by traditional drugs, third-quarter results are still under pressure
Xiangxue Pharmaceutical (300147) Quarterly report comments: traditional drugs drag down the third quarter results are still under pressure
Xiangxue Pharmaceutical (300147) newspaper comments: marketing reform drags traditional business TCRT forward in an orderly manner
[GF Securities Co., LTD.] Xiangxue Pharmaceutical: marketing reform drags down traditional business, TCRT advances in an orderly manner
香雪制药(300147)：收购兆阳生物 增强当地终端把控能力
【广发证券】香雪制药:收购兆阳生物,增强当地终端把控能力
【广发证券】香雪制药:布局多个中药产业园,全产业链持续扩张
香雪制药(300147)：布局多个中药产业园 全产业链持续扩张
香雪制药(300147)一季报点评：一季报符合预期 业绩有望逐步向好
【广发证券】香雪制药:一季报符合预期,业绩有望逐步向好
香雪制药(300147)年报点评：中药产业整合者 怎能错过?
【东吴证券】香雪制药:中药产业整合者,怎能错过?
香雪制药(300147)年报点评：业绩低于预期 长期看好公司发展
香雪制药(300147)年报点评：传统业务内生改善 精准医疗大有可为
Analysis
Price Target
No Data
No Data